MC
DMAAR

Meteora Capital’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Meteora Capital’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11K Buy
182,581
+180,581
+9,029% +$19.1K ﹤0.01% 311
2025
Q4 		$375 Buy
+2,000
New +$388 ﹤0.01% 359

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Meteora Capital's DMAAR Position: Q1 2026 in Review

Meteora Capital increased its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 9,029% in Q1 2026, buying an estimated $19.1K and bringing the position to 182,581 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #311.

Meteora Capital first reported a position in DMAAR in Q4 2025 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • Meteora Capital held 182,581 shares of Drugs Made In America Acquisition Corp Rights worth $11K as of Q1 2026.
  • Meteora Capital bought 180,581 Drugs Made In America Acquisition Corp Rights shares in Q1 2026, an estimated $19.1K.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Meteora Capital's portfolio in Q1 2026, its #311 holding.
  • Meteora Capital first reported a position in Drugs Made In America Acquisition Corp Rights in Q4 2025 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on Meteora Capital's 13F filing for Q1 2026, filed 15 May 2026.